BIVI Key Statistics, Chart & Performance
The current stock price of BIVI is 1.13 USD. In the past month the price decreased by -24.92%. In the past year, price decreased by -94.93%.
BIVI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.31 | 406.04B | ||
| AMGN | AMGEN INC | 15.03 | 176.99B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.14 | 115.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.92 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 31.74B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 21.37B | ||
| INCY | INCYTE CORP | 15.41 | 19.42B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About BIVI
Company Profile
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company is headquartered in Carson City, Nevada and currently employs 13 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Company Info
BIOVIE INC
680 W Nye Lane, Suite 201
Carson City NEVADA 90404 US
CEO: Cuong Do
Employees: 13
Phone: 17758883162
BIOVIE INC / BIVI FAQ
What does BIVI do?
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company is headquartered in Carson City, Nevada and currently employs 13 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
What is the current price of BIVI stock?
The current stock price of BIVI is 1.13 USD. The price decreased by -8.13% in the last trading session.
Does BIOVIE INC pay dividends?
BIVI does not pay a dividend.
What is the ChartMill technical and fundamental rating of BIVI stock?
BIVI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for BIOVIE INC?
BIOVIE INC (BIVI) currently has 13 employees.
Can you provide the market cap for BIOVIE INC?
BIOVIE INC (BIVI) has a market capitalization of 8.52M USD. This makes BIVI a Nano Cap stock.
Can you provide the ownership details for BIVI stock?
You can find the ownership structure of BIOVIE INC (BIVI) on the Ownership tab.
BIVI Technical Analysis
BIVI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BIVI. While BIVI has a great health rating, there are worries on its profitability.
BIVI Financial Highlights
Over the last trailing twelve months BIVI reported a non-GAAP Earnings per Share(EPS) of -8.92. The EPS increased by 84.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.22% | ||
| ROE | -74.5% | ||
| Debt/Equity | 0 |
BIVI Forecast & Estimates
7 analysts have analysed BIVI and the average price target is 12.24 USD. This implies a price increase of 983.19% is expected in the next year compared to the current price of 1.13.